scholarly journals Venetoclax and Hypomethylating agents in Older/Unfit patients with Blastic Plasmacytoid Dendritic Cell Neoplasm ( BPDCN )

2021 ◽  
Author(s):  
Naseema Gangat ◽  
Marina Konopleva ◽  
Mrinal M. Patnaik ◽  
Elias Jabbour ◽  
Courtney DiNardo ◽  
...  
Keyword(s):  
Dendritic Cell ◽  
Plasmacytoid Dendritic Cell ◽  
Hypomethylating Agents ◽  
Cell Neoplasm ◽  
Unfit Patients

Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope

2020 ◽  
Vol 111 (5) ◽  
Author(s):  
Delia Cangini ◽  
Paolo Silimbani ◽  
Alessandro Cafaro ◽  
Maria B. Giannini ◽  
Carla Masini ◽  
...  
Keyword(s):  
Dendritic Cell ◽  
Plasmacytoid Dendritic Cell ◽  
Cell Neoplasm

scholarly journals Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications

Haematologica ◽  
2010 ◽  
Vol 95 (11) ◽  
pp. 1873-1879 ◽  
Author(s):  
A. G. Jegalian ◽  
N. P. Buxbaum ◽  
F. Facchetti ◽  
M. Raffeld ◽  
S. Pittaluga ◽  
...  
Keyword(s):  
Dendritic Cell ◽  
Plasmacytoid Dendritic Cell ◽  
Clinical Implications ◽  
Diagnostic Features ◽  
Cell Neoplasm

scholarly journals Blastic plasmacytoid dendritic cell neoplasm with genetic mutations in multiple epigenetic modifiers: a case report

2021 ◽  
Vol 49 (2) ◽  
pp. 030006052098266
Author(s):  
Xinmei Dang ◽  
Di Zhou ◽  
Lingjun Meng ◽  
Lintao Bi
Keyword(s):  
Dendritic Cell ◽  
Plasmacytoid Dendritic Cell ◽  
Genetic Mutations ◽  
Cell Surface Markers ◽  
Targeted Therapeutics ◽  
Genetic Studies ◽  
Clinical Prognosis ◽  
Epigenetic Modifiers ◽  
Cell Neoplasm ◽  
Underlying Pathogenesis

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematodermic malignancy derived from plasmacytoid dendritic cell precursors. Despite advances in our understanding of tumor cell surface markers, the pathogenesis of BPDCN remains largely unknown. No standard or optimal treatments are available for BPDCN, and the prognosis is usually poor. We report herein a case of BPDCN that harbored multiple genetic mutations in epigenetic modifiers such as TET2 and ZRSR2. Genetic studies in patients with BPDCN may provide insights into the underlying pathogenesis, prediction of clinical prognosis, and development of better targeted therapeutics for this rare clinical entity.

Sign in / Sign up

Export Citation Format

Share Document